Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 3Genitourinary 2Gastrointestinal 2Breast 2Thoracic 1Plasma cell 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1Dermatologic 1Classical hematology 1

Conditions

Ovarian Neoplasms 2Lung Neoplasms 2Triple Negative Breast Neoplasms 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Melanoma 1Fallopian Tube Neoplasms 1Colorectal Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Adenocarcinoma of Lung 1

Interventions

pembrolizumab 48Carboplatin 34Pemetrexed 28Cisplatin 25Docetaxel 23Nivolumab 21Paclitaxel 20Gemcitabine 15Magnetic Resonance Spectroscopy 14Specimen Handling 12Radiotherapy 12Cyclophosphamide 12Radiosurgery 11130-nm albumin-bound paclitaxel 11Erlotinib Hydrochloride 10Bevacizumab 10osimertinib 9Cetuximab 8Temozolomide 7Taxes 7Ipilimumab 7Biopsy 7fludarabine 6Ramucirumab 6Radiation 6veliparib 5tislelizumab 5durvalumab 5cemiplimab 5atezolizumab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasm Metastasis × dehydroftorafur × Thoracic × Clear all
NCT02419495 2025-06-04

Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies

M.D. Anderson Cancer Center

Phase 1 Terminated
221 enrolled
BreastDermatologicGenitourinaryGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Fallopian Tube Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Ovarian Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡